{
    "xml": "<topic id=\"PHP3775\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/tenofovir-disoproxil\" basename=\"tenofovir-disoproxil\" title=\"TENOFOVIR DISOPROXIL\">\n<title>TENOFOVIR DISOPROXIL</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_954\" namespace=\"/interactions/list-of-drug-interactions/antivirals/tenofovir\">Tenofovir</xref>\n</p>\n<data name=\"vtmid\">395264002</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_149321041\" title=\"Nucleoside reverse transcriptase inhibitors\">Nucleoside reverse transcriptase inhibitors</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34645\" title=\"NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS\" namespace=\"/drug-classes/nucleoside-reverse-transcriptase-inhibitors\">NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP40771\" outputclass=\"indicationsAndDose\" rev=\"1.30\" parent=\"/drugs/tenofovir-disoproxil\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">HIV infection in combination with other antiretroviral drugs</p>\n<p outputclass=\"therapeuticIndication\">Chronic hepatitis B infection with compensated liver disease (with evidence of viral replication, and histologically documented active liver inflammation or fibrosis)</p>\n<p outputclass=\"therapeuticIndication\">Chronic hepatitis B infection with decompensated liver disease</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>245&#8239;mg once daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseEquivalence\">\n<title>Dose equivalence and conversion</title>\n<p>7.5 scoops of granules contains approx. 245&#8239;mg tenofovir disoproxil (as fumarate).</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40768\" outputclass=\"interactions\" rev=\"1.9\" parent=\"/drugs/tenofovir-disoproxil\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (tenofovir).</p>\n<p>Use with caution if concomitant or recent use of nephrotoxic drugs.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40743\" outputclass=\"sideEffects\" rev=\"1.12\" parent=\"/drugs/tenofovir-disoproxil\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Nephrogenic diabetes insipidus</ph>; <ph outputclass=\"sideEffect\">proximal renal tubulopathy</ph>; <ph outputclass=\"sideEffect\">renal failure</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hypophosphataemia</ph>; <ph outputclass=\"sideEffect\">reduced bone density</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40753\" outputclass=\"renalImpairment\" parent=\"/drugs/tenofovir-disoproxil\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>\n<i>Granules</i>: 132&#8239;mg once daily if eGFR 30&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; 66&#8239;mg once daily if eGFR 20&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; 33&#8239;mg once daily if eGFR 10&#8211;20&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n<p>\n<i>Tablets</i>: 245&#8239;mg every 2 days if eGFR 30&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; 245&#8239;mg every 3&#8211;4 days if eGFR 10&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInRenalImpairment\">\n<sectiondiv>\n<p>Monitor renal function&#8212;interrupt treatment if further deterioration.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40713\" outputclass=\"monitoringRequirements\" parent=\"/drugs/tenofovir-disoproxil\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Test renal function and serum phosphate before treatment, then every 4 weeks (more frequently if at increased risk of renal impairment) for 1 year and then every 3 months, interrupt treatment if renal function deteriorates or serum phosphate decreases.</p>\n</sectiondiv>\n<sectiondiv>\n<p>When treating chronic hepatitis B with tenofovir, monitor liver function tests every 3 months and viral markers for hepatitis B every 3&#8211;6 months during treatment (continue monitoring for at least 1 year after discontinuation&#8212;recurrent hepatitis may occur on discontinuation).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40817\" outputclass=\"directionsForAdministration\" rev=\"1.18\" parent=\"/drugs/tenofovir-disoproxil\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>\n<i>Granules</i>: mix 1 scoop of granules with 1 tablespoon of soft food (e.g. yoghurt, apple sauce) and take immediately without chewing. Do <b>not</b> mix granules with liquids.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40757\" outputclass=\"patientAndCarerAdvice\" rev=\"1.15\" parent=\"/drugs/tenofovir-disoproxil\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"adviceAroundMissedDoses\">\n<title>Missed doses</title>\n<sectiondiv>\n<p>If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p>Patients or carers should be given advice on how to administer tenofovir granules.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP40685\" outputclass=\"nationalFunding\" rev=\"1.21\" parent=\"/drugs/tenofovir-disoproxil\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA173</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Tenofovir disoproxil for the treatment of chronic hepatitis B (July 2009)</p>\r\n<p>Tenofovir is an option for the treatment of chronic hepatitis B.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA173\">www.nice.org.uk/TA173</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP3775-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/tenofovir-disoproxil\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77075\" title=\"Tablet\" namespace=\"/drugs/tenofovir-disoproxil/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77082\" title=\"Granules\" namespace=\"/drugs/tenofovir-disoproxil/granules\">Granules</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85586\" namespace=\"/drugs/cobicistat-with-elvitegravir-emtricitabine-and-tenofovir\" title=\"COBICISTAT WITH ELVITEGRAVIR, EMTRICITABINE AND TENOFOVIR\" count=\"1\" rel=\"backlink\">COBICISTAT WITH ELVITEGRAVIR, EMTRICITABINE AND TENOFOVIR</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85593\" namespace=\"/drugs/efavirenz-with-emtricitabine-and-tenofovir\" title=\"EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR\" count=\"1\" rel=\"backlink\">EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP85595\" namespace=\"/drugs/emtricitabine-with-rilpivirine-and-tenofovir\" title=\"EMTRICITABINE WITH RILPIVIRINE AND TENOFOVIR\" count=\"1\" rel=\"backlink\">EMTRICITABINE WITH RILPIVIRINE AND TENOFOVIR</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP97003\" namespace=\"/drugs/emtricitabine-with-tenofovir\" title=\"EMTRICITABINE WITH TENOFOVIR\" count=\"1\" rel=\"backlink\">EMTRICITABINE WITH TENOFOVIR</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78240\" namespace=\"/treatment-summaries/hepatitis\" title=\"Hepatitis\" count=\"7\" rel=\"backlink\">Hepatitis</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78275\" namespace=\"/treatment-summaries/hiv-infection\" title=\"HIV infection\" count=\"2\" rel=\"backlink\">HIV infection</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_954\" namespace=\"/interactions/list-of-drug-interactions/antivirals/tenofovir\" title=\"Tenofovir\" count=\"1\" rel=\"link\">Tenofovir</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34645\" namespace=\"/drug-classes/nucleoside-reverse-transcriptase-inhibitors\" title=\"NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS\" count=\"1\" rel=\"link\">NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77075\" namespace=\"/drugs/tenofovir-disoproxil/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77082\" namespace=\"/drugs/tenofovir-disoproxil/granules\" title=\"Granules\" count=\"1\" rel=\"link\">Granules</xref>\n</links>\n</topic>",
    "id": "PHP3775",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/tenofovir-disoproxil",
    "basename": "tenofovir-disoproxil",
    "title": "TENOFOVIR DISOPROXIL",
    "interactants": [
        {
            "id": "bnf_int_954",
            "label": "Tenofovir"
        }
    ],
    "vtmid": "395264002",
    "drugClassification": [
        "Nucleoside reverse transcriptase inhibitors"
    ],
    "inheritsFromClass": [
        "NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "HIV infection in combination with other antiretroviral drugs",
                        "html": "HIV infection in combination with other antiretroviral drugs"
                    },
                    {
                        "textContent": "Chronic hepatitis B infection with compensated liver disease (with evidence of viral replication, and histologically documented active liver inflammation or fibrosis)",
                        "html": "Chronic hepatitis B infection with compensated liver disease (with evidence of viral replication, and histologically documented active liver inflammation or fibrosis)"
                    },
                    {
                        "textContent": "Chronic hepatitis B infection with decompensated liver disease",
                        "html": "Chronic hepatitis B infection with decompensated liver disease"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "245 mg once daily.",
                        "html": "<p>245&#8239;mg once daily.</p>"
                    }
                ]
            }
        ],
        "doseEquivalence": [
            {
                "type": "doseEquivalence",
                "title": "Dose equivalence and conversion",
                "textContent": "7.5 scoops of granules contains approx. 245 mg tenofovir disoproxil (as fumarate).",
                "html": "<p>7.5 scoops of granules contains approx. 245&#8239;mg tenofovir disoproxil (as fumarate).</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (tenofovir).\n\nUse with caution if concomitant or recent use of nephrotoxic drugs.",
                "html": "<p>Appendix 1 (tenofovir).</p><p>Use with caution if concomitant or recent use of nephrotoxic drugs.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Nephrogenic diabetes insipidus",
                        "html": "Nephrogenic diabetes insipidus",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "proximal renal tubulopathy",
                        "html": "proximal renal tubulopathy",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "renal failure",
                        "html": "renal failure",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Hypophosphataemia",
                        "html": "Hypophosphataemia",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "reduced bone density",
                        "html": "reduced bone density",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Granules: 132 mg once daily if eGFR 30&#8211;50 mL/minute/1.73 m2; 66 mg once daily if eGFR 20&#8211;30 mL/minute/1.73 m2; 33 mg once daily if eGFR 10&#8211;20 mL/minute/1.73 m2.\n\nTablets: 245 mg every 2 days if eGFR 30&#8211;50 mL/minute/1.73 m2; 245 mg every 3&#8211;4 days if eGFR 10&#8211;30 mL/minute/1.73 m2.",
                "html": "<p>\n<i>Granules</i>: 132&#8239;mg once daily if eGFR 30&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; 66&#8239;mg once daily if eGFR 20&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; 33&#8239;mg once daily if eGFR 10&#8211;20&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p><p>\n<i>Tablets</i>: 245&#8239;mg every 2 days if eGFR 30&#8211;50&#8239;mL/minute/1.73&#8239;m<sup>2</sup>; 245&#8239;mg every 3&#8211;4 days if eGFR 10&#8211;30&#8239;mL/minute/1.73&#8239;m<sup>2</sup>.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "Monitor renal function&#8212;interrupt treatment if further deterioration.",
                "html": "<p>Monitor renal function&#8212;interrupt treatment if further deterioration.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Test renal function and serum phosphate before treatment, then every 4 weeks (more frequently if at increased risk of renal impairment) for 1 year and then every 3 months, interrupt treatment if renal function deteriorates or serum phosphate decreases.",
                "html": "<p>Test renal function and serum phosphate before treatment, then every 4 weeks (more frequently if at increased risk of renal impairment) for 1 year and then every 3 months, interrupt treatment if renal function deteriorates or serum phosphate decreases.</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "When treating chronic hepatitis B with tenofovir, monitor liver function tests every 3 months and viral markers for hepatitis B every 3&#8211;6 months during treatment (continue monitoring for at least 1 year after discontinuation&#8212;recurrent hepatitis may occur on discontinuation).",
                "html": "<p>When treating chronic hepatitis B with tenofovir, monitor liver function tests every 3 months and viral markers for hepatitis B every 3&#8211;6 months during treatment (continue monitoring for at least 1 year after discontinuation&#8212;recurrent hepatitis may occur on discontinuation).</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "Granules: mix 1 scoop of granules with 1 tablespoon of soft food (e.g. yoghurt, apple sauce) and take immediately without chewing. Do not mix granules with liquids.",
                "html": "<p>\n<i>Granules</i>: mix 1 scoop of granules with 1 tablespoon of soft food (e.g. yoghurt, apple sauce) and take immediately without chewing. Do <b>not</b> mix granules with liquids.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "adviceAroundMissedDoses": [
            {
                "type": "adviceAroundMissedDoses",
                "textContent": "If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.",
                "html": "<p>If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.</p>"
            }
        ],
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "textContent": "Patients or carers should be given advice on how to administer tenofovir granules.",
                "html": "<p>Patients or carers should be given advice on how to administer tenofovir granules.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA173",
                        "label": "www.nice.org.uk/TA173"
                    }
                ],
                "fundingIdentifier": "NICE TA173",
                "textContent": "Tenofovir disoproxil for the treatment of chronic hepatitis B (July 2009) Tenofovir is an option for the treatment of chronic hepatitis B.\n\nwww.nice.org.uk/TA173",
                "html": "<p outputclass=\"title\">Tenofovir disoproxil for the treatment of chronic hepatitis B (July 2009)</p> <p>Tenofovir is an option for the treatment of chronic hepatitis B.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA173\">www.nice.org.uk/TA173</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77075",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77082",
                "label": "Granules",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drug": [
            {
                "id": "PHP85586",
                "label": "COBICISTAT WITH ELVITEGRAVIR, EMTRICITABINE AND TENOFOVIR",
                "type": "drug"
            },
            {
                "id": "PHP85593",
                "label": "EFAVIRENZ WITH EMTRICITABINE AND TENOFOVIR",
                "type": "drug"
            },
            {
                "id": "PHP85595",
                "label": "EMTRICITABINE WITH RILPIVIRINE AND TENOFOVIR",
                "type": "drug"
            },
            {
                "id": "PHP97003",
                "label": "EMTRICITABINE WITH TENOFOVIR",
                "type": "drug"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78240",
                "label": "Hepatitis",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78275",
                "label": "HIV infection",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_954",
                "label": "Tenofovir",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34645",
                "label": "NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77075",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP77082",
                "label": "Granules",
                "type": "medicinalForm"
            }
        ]
    }
}